JPH0352818A - Remedy for osteoporosis - Google Patents
Remedy for osteoporosisInfo
- Publication number
- JPH0352818A JPH0352818A JP1188046A JP18804689A JPH0352818A JP H0352818 A JPH0352818 A JP H0352818A JP 1188046 A JP1188046 A JP 1188046A JP 18804689 A JP18804689 A JP 18804689A JP H0352818 A JPH0352818 A JP H0352818A
- Authority
- JP
- Japan
- Prior art keywords
- extract
- therapeutic agent
- horn
- remedy
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000001132 Osteoporosis Diseases 0.000 title claims abstract description 8
- 239000003814 drug Substances 0.000 claims abstract description 32
- 241001465754 Metazoa Species 0.000 claims abstract description 8
- 229940124597 therapeutic agent Drugs 0.000 claims description 24
- 241000282994 Cervidae Species 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 23
- 239000000284 extract Substances 0.000 abstract description 18
- 239000000843 powder Substances 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 5
- 239000000706 filtrate Substances 0.000 abstract description 5
- 238000001914 filtration Methods 0.000 abstract description 2
- 230000002879 macerating effect Effects 0.000 abstract 1
- 239000002904 solvent Substances 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 210000000988 bone and bone Anatomy 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 241001061526 Pluteus cervinus Species 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 239000005711 Benzoic acid Substances 0.000 description 2
- 241000282985 Cervus Species 0.000 description 2
- 241000283007 Cervus nippon Species 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000237502 Ostreidae Species 0.000 description 2
- 210000003056 antler Anatomy 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 235000020636 oyster Nutrition 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229940098465 tincture Drugs 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000283026 Cervus elaphus Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241001416180 Moschidae Species 0.000 description 1
- 241000282943 Odocoileus Species 0.000 description 1
- 206010067572 Oestrogenic effect Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000283011 Rangifer Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001390 capsicum minimum Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- -1 for example Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 238000001238 wet grinding Methods 0.000 description 1
Abstract
Description
【発明の詳細な説明】 〔産業上の利用分野〕 本発明は、骨粗然症治療剤に関する。[Detailed description of the invention] [Industrial application field] The present invention relates to a therapeutic agent for osteoporosis.
骨粗継症は骨の中のカルシウム、タンパク質、リンの量
が減少するために骨の密度が小さくなり、骨が非常にも
ろくなる症状をいい、高齢者、特に閉経後の女性に多く
みられる。Osteoporosis is a condition in which the amount of calcium, protein, and phosphorus in the bones decreases, resulting in a decrease in bone density and bone fragility, and is common in the elderly, especially in postmenopausal women. .
この骨粗稲症の治療には女性ホルモンであるエストロゲ
ン、ビタミンＤあるいはカルチトニン等の合成薬剤の投
与が一般に行なわれているが、合成薬剤の投与には通常
副作用が伴ない余り好ましくない。To treat this osteoporosis, synthetic drugs such as the female hormone estrogen, vitamin D, or calcitonin are generally administered, but the administration of synthetic drugs is usually accompanied by side effects and is not very desirable.
本発明は、天然物を用いた副作用のない骨阻壓症治療剤
を提供することを目的とする。An object of the present invention is to provide a therapeutic agent for osteoarthritis that uses natural products and has no side effects.
上記目的を達成するため、シカ科に属する動物の角を使
用すれば、優れた功を奏することを見出し、本発明を威
すに至った。In order to achieve the above object, the present inventors have discovered that the use of the horns of animals belonging to the deer family produces excellent results, and has come to realize the present invention.
即ち本発明は、シカ科に属する動物の角からなる骨粗壓
症治療剤を提供する。That is, the present invention provides a therapeutic agent for osteoporosis comprising the horns of animals belonging to the family Cervidae.
上記シカ科に属する動物は、特に限定されず例えばニホ
ンジカ、アカシカ、トナカイ、オジロノカ、ジャコウジ
カ等が挙げられる。The animals belonging to the deer family are not particularly limited, and include, for example, Japanese deer, red deer, reindeer, white-tailed deer, musk deer, and the like.
本発明の治療剤は上記シカ科の動物（以下、単にシカと
いう。）の角を使用する。シカの角はその生長の時期、
部位等に無関係に使用することができる。好ましくは一
般に漢方の分野で鹿茸（ロクノヨウ）（即ち、シカ科の
動物の中のシカ（ Ｃ ｅｒｖｕｓｎｉｐｐｏｎ Ｔｅ
ｍｍｉｎｃｋ）またはアカシカ（Ｃ ．ｅｌａｐｈｕｓ
Ｌ）の雄のまだ骨化していない幼角）として知られてい
るものである。The therapeutic agent of the present invention uses the antlers of the deer family (hereinafter simply referred to as deer). Deer antlers grow during their growth period.
It can be used regardless of the location. Preferably, deer mushroom (Cervusnippon Te), which is commonly used in the field of Chinese medicine,
mminck) or red deer (C. elaphus
This is known as the unossified juvenile horn of the male L).
上記角は、治療剤の形態例えば丸剤、錠剤、顆粒剤、カ
プセル剤及び液剤等に応じて適当な形、例えば粉体物と
して或るいはエキスとして配合しても良い。本発明の治
療剤が丸剤、錠剤、顆粒剤等である場合は、上記角をそ
のまま粉体としてまたはエタノールなどの極性溶媒で抽
出したエキスとして配合されるのが好ましい。The above-mentioned horns may be formulated in a suitable form, for example, as a powder or as an extract, depending on the form of the therapeutic agent, such as pills, tablets, granules, capsules, liquids, etc. When the therapeutic agent of the present invention is in the form of pills, tablets, granules, etc., it is preferable that the above-mentioned horns be blended as a powder or as an extract extracted with a polar solvent such as ethanol.
本発明の治療剤が液剤等である場合は、上記角はエキス
、あるいはチンキ等として配合する。エキス及びチンキ
等の詞製法としては通常の方法であってよい。例えばエ
キス等の調製法として以下が例示さ五る。上記角の粉末
を抽出溶媒中で冷浸し、濾過して濾液を得る。残留物に
ついては上記冷浸、濾過を２〜３回繰り返す。得られた
濾液を合わせ、抽出溶媒を留去して濃縮してエキスを得
る。尚、冷浸中時々撹拌するのが好ましい。When the therapeutic agent of the present invention is in the form of a liquid or the like, the above-mentioned horns are blended as an extract, tincture, or the like. Extracts, tinctures, etc. may be produced by any conventional method. For example, the following are exemplified as methods for preparing extracts and the like. The horn powder is chilled in an extraction solvent and filtered to obtain a filtrate. For the residue, repeat the above cooling and filtration process 2 to 3 times. The obtained filtrates are combined and concentrated by distilling off the extraction solvent to obtain an extract. In addition, it is preferable to stir occasionally during cooling.
上記抽出溶媒としては例えば、水及びメタノール、エタ
ノール等のアルコール類並びにこれらの混合物等が挙げ
られるが、好ましくは含水エタノールである。抽出溶媒
の使用量は角の粉体ｌ重量部に対して２〜１０重量部、
好ましくは４〜５重量部である。２重量部より少ないと
エキスが十分抽出されず又、１０ｆｆｉｆｆｉ部より多
いと経済的に不利となる。Examples of the extraction solvent include water, alcohols such as methanol and ethanol, and mixtures thereof, and preferably water-containing ethanol. The amount of extraction solvent used is 2 to 10 parts by weight per 1 part by weight of the corner powder.
Preferably it is 4 to 5 parts by weight. If it is less than 2 parts by weight, the extract will not be extracted sufficiently, and if it is more than 10 ffiffi parts, it will be economically disadvantageous.
上記冷浸温度及び時間は、５〜４０℃、好ましくは１５
〜２５℃で、ｌ〜５日間、好ましくは２〜３日間である
。５℃より低かったり、又は、１日間より短かいとエキ
スが十分抽出されない。４０℃より高いと内容成分の分
解が起こり易くなり、又、３日間より長いと内容成分と
溶媒が化学反応を起こす場合が考えられ好ましくない。The above cooling temperature and time are 5 to 40°C, preferably 15°C.
~25° C. for 1 to 5 days, preferably 2 to 3 days. If the temperature is lower than 5°C or shorter than 1 day, the extract will not be extracted sufficiently. If the temperature is higher than 40°C, decomposition of the contents will easily occur, and if it is longer than 3 days, a chemical reaction may occur between the contents and the solvent, which is not preferable.
上記濃縮操作に於いては、常圧下でも減圧下でもよいが
、濃縮温度が４０℃以下で行なうのが好ましい。４０°
Ｃより高いと含有蛋白質等熱に不安定な未知物質が変性
し、薬効に影響を与えると考えられるので好ましくない
。The above concentration operation may be carried out under normal pressure or reduced pressure, but it is preferably carried out at a concentration temperature of 40° C. or lower. 40°
If it is higher than C, thermally unstable unknown substances such as proteins contained therein are denatured, which is considered to affect the drug efficacy, which is not preferable.
本発明の治療剤に於いては、上記粉体若しくはエキスの
他に治療剤に通常配合されるもの、例えば、治療剤が錠
剤等の場合、賦形剤等、又治療剤が液剤等の場合、可溶
化剤、溶解補助剤、防腐剤等が配合される。In the therapeutic agent of the present invention, in addition to the above-mentioned powders or extracts, substances that are usually added to therapeutic agents, such as when the therapeutic agent is in the form of a tablet or the like, excipients, etc., or when the therapeutic agent is in the form of a liquid agent, etc. , a solubilizer, a solubilizing agent, a preservative, etc.
可溶化剤としては例えば、ニツコールＨＣＯ−６０（日
本サーファクタント工業製）、及びユニオツクスＨＣ−
６０（日本油脂製）等が挙げられる。又溶解浦助剤とし
ては例えばエタノール及びグリセリン等が挙げられる。Examples of solubilizers include Nikkor HCO-60 (manufactured by Nippon Surfactant Industries) and Uniotx HC-60 (manufactured by Nippon Surfactant Industries).
60 (manufactured by NOF Corporation) and the like. Examples of the solubilizing agent include ethanol and glycerin.
更に防腐剤としてはパラオキシ安息香酸エチル、安息香
酸及びこれらの混合物等が挙げられる。Furthermore, examples of preservatives include ethyl paraoxybenzoate, benzoic acid, and mixtures thereof.
本発明の治療剤の組成に於いて、上記角の粉体若しくは
エキスの量は、治療剤の０．５〜５重量％、好ましくは
１〜２重量％である。In the composition of the therapeutic agent of the present invention, the amount of the horn powder or extract is 0.5-5% by weight, preferably 1-2% by weight of the therapeutic agent.
その他の添加剤として例えば、矯味剤、甘味剤及び着色
剤等を配合しても良い。As other additives, for example, flavoring agents, sweeteners, coloring agents, etc. may be added.
本発明の治療剤の製剤法は通常の方法でよく、例えば錠
剤として製剤する場合は、上記各配合剤をトウモロコシ
デンブン等で均一に混合しこれを例えば錠剤成型機等で
５０〜５００ｕ、好ましくはｌＯＯ〜２００ｕ９の錠剤
に戊型してもよい。The therapeutic agent of the present invention may be formulated by a conventional method. For example, in the case of preparing a tablet, the above-mentioned ingredients are uniformly mixed with corn starch, etc., and then the mixture is heated to 50 to 500 u, preferably in a tablet molding machine. may be molded into tablets of lOO~200u9.
また液剤として製剤する場合は、上記各配合剤をニッコ
ール等で均一に撹拌混合した１０〜１００ ｍＱ，好ま
しくは２５〜５０ｍ（！の肢剤を、適当な容器、例えば
ガラス瓶等に入れてこれを治療剤としても良い。In addition, when preparing a liquid preparation, the above-mentioned ingredients are uniformly stirred and mixed with a Nikkor, etc., and then 10 to 100 mQ, preferably 25 to 50 m It can also be used as a therapeutic agent.
本発明の治療剤の服用量は、戊人に対し、その角のエキ
スを２００〜５ＱＯｔ９／１日投与する量である。角の
エキスの投与量が２００ｘｙ／ｌ日より少ないと本発明
の治療効果が得られず、又５００ｍｇ７１日より多いと
合成薬剤の様に副作用発生の恐れはないが、高価な原料
であるため、経済上不都合であり好ましくない。The dose of the therapeutic agent of the present invention is such that the extract of the horn is administered to a human with 200 to 5 QOt9/day. If the dose of horn extract is less than 200xy/l day, the therapeutic effect of the present invention cannot be obtained, and if it is more than 500mg/71 days, there is no risk of side effects like synthetic drugs, but since it is an expensive raw material, This is economically inconvenient and undesirable.
本発明により、骨粗鬆症の予防および治療に非常に有効
で且つ副作用のない治療剤を提供することが出来る。According to the present invention, it is possible to provide a therapeutic agent that is highly effective in preventing and treating osteoporosis and has no side effects.
〔実施例〕
以下本発明を実施例で更に詳細に説明するが、本発明は
これら実施例に限定されるものではない。[Examples] The present invention will be explained in more detail by Examples below, but the present invention is not limited to these Examples.
実施例！
２００メッシュ以下に粉砕した鹿茸５ｇにトウモロコシ
デンブン粉末ｌｏｇ、乳糖粉末２０ｇ、カルボキシメチ
ルセルロースカルンウム粉末１０ｇ，微結晶セルロース
４０ｇ１ボリピニルビロリドン扮末５ｇ及びタルク粉末
１０ｇを添加して均一に混合し、常法により湿式造拉し
、これを錠剤或型機にて１錠２００Ｈの錠剤を凋製した
。Example! Add log corn starch powder, 20 g of lactose powder, 10 g of carboxymethyl cellulose carunium powder, 40 g of microcrystalline cellulose, 5 g of voripinyl pyrrolidone powder, and 10 g of talc powder to 5 g of deer mushrooms crushed to 200 mesh or less, and mix uniformly. , Wet milling was carried out using a conventional method, and the resulting product was milled into tablets of 200H each using a tablet molding machine.
実施例２
２００メソシュ以下に粉砕した鹿茸５ｇを、５０％エタ
ノール３０ｍ（で時々撹拌しながら室温で３日間冷浸し
た。次いて濾過し濾液を分取した。Example 2 5 g of deer mushrooms crushed to 200 mesosh or less were cold-soaked in 30 mL of 50% ethanol at room temperature for 3 days with occasional stirring.Then, it was filtered and the filtrate was collected.
同じ操作を３回繰り返し、すべての濾液を合わして１０
０ｍｍｌ｛ｇの減圧下４０°Ｃ以下でエタノールを留去
しａ縮して鹿茸エキスを得た。Repeat the same operation 3 times and combine all filtrates for 10
Ethanol was distilled off and condensed at 40°C or lower under a reduced pressure of 0 mml{g to obtain a deer mushroom extract.
次いで上記鹿茸エキス３ ０ ０ ｍｇ，ニッコールＨ
Ｃ○−６０ １２０ｘ９、トウガラソチンキ０．０５
ｍｌ２，白糖５ｇ，エタノール０ ． ５ ｍＱ，パラ
オキシ安息香酸エチル２４７１ｇ及び安息香酸２ス９を
よく混合して均一溶液を得た。この溶液３０ｍ９をアン
プル瓶に入れて治療剤を得た。Next, 300 mg of the above deer mushroom extract, Nikkor H
C○-60 120x9, Capsicum tincture 0.05
ml2, white sugar 5g, ethanol 0. 5 mQ, 2471 g of ethyl paraoxybenzoate, and 2 s of benzoic acid were thoroughly mixed to obtain a homogeneous solution. 30 ml of this solution was put into an ampoule bottle to obtain a therapeutic agent.
薬理活性及び毒性試験
試験例１
内因性エストロゲン作用を取り除くために卵巣摘除を行
った６週令ウィスター（Ｗｉｓｔａｒ）系ラットを用い
て薬理活性試験した。ラット６匹に対しては実施例２の
治療剤を体重１ｋｇ当り１５０ｘｙの服用量で毎日４週
間経口投与した。又別のラット７匹に対しては牡蛎（イ
タボガキ科に属する貝類）を体重１ｋｇ当り５００ｘｇ
の服用量で毎日４週間経口投与した。更に別のラット６
匹に対しては対照動物として薬剤を全く投与しなかった
。４週間後に各ラットの骨重量、天分量及び骨折破力を
測定して薬理活性を調べた。測定結果を表−１に示す。Pharmacological Activity and Toxicity Test Test Example 1 Pharmacological activity was tested using 6-week-old Wistar rats whose ovaries were removed to eliminate endogenous estrogenic effects. The therapeutic agent of Example 2 was orally administered to 6 rats at a dose of 150xy/kg body weight every day for 4 weeks. For another 7 rats, 500xg of oysters (shellfish belonging to the oyster family) were added per 1kg of body weight.
The dose was orally administered daily for 4 weeks. Yet another rat 6
The animals served as control animals and received no drug. Four weeks later, the bone weight, natural mass, and fracture force of each rat were measured to examine the pharmacological activity. The measurement results are shown in Table-1.
表一ｌに示したように本発明の治療剤を投与したラソト
は、投与しなかったラットに比べ骨生育の度合の指標で
ある骨乾燥重量、天分量及び骨折破力共に増加し、顕著
な骨強化作用が詠められる。As shown in Table 1l, the rats to which the therapeutic agent of the present invention was administered showed an increase in bone dry weight, bone mass, and fracture fracture strength, which are indicators of the degree of bone growth, compared to rats to which the therapeutic agent of the present invention was not administered. It is said to have a bone-strengthening effect.
表一ｌ １），２）：ラット１群当たりの平均値士標準偏差。Table 1 1), 2): Mean value and standard deviation per group of rats.
３）・ラット脛骨の骨折破力（骨破壊機にて測定）試験
例２
ｌＯ匹のｄｄ−Ｙ系雄性マウスに水、飼料とも自由に与
えて実施例１及び２の治療剤をそれぞれ体重１ｋｇ当た
り２０００Ｒｇの服用量で毎日１週間経口投与して毒性
試験した。１週間マウスを観察した結果死亡例はなく、
又中毒症状も全く見られなかったことより、本発明の治
療剤は全く毒性がないことが判った。3) - Fracture fracture force of rat tibia (measured using a bone crusher) Test Example 2 10 male dd-Y mice were given water and feed ad libitum, and each of the therapeutic agents of Examples 1 and 2 was administered at a weight of 1 kg. A toxicity test was conducted by orally administering the drug at a dose of 2000 Rg per day for one week. After observing the mice for one week, there were no deaths.
Furthermore, no toxic symptoms were observed, indicating that the therapeutic agent of the present invention is completely non-toxic.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1188046A JPH0352818A (en) | 1989-07-20 | 1989-07-20 | Remedy for osteoporosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1188046A JPH0352818A (en) | 1989-07-20 | 1989-07-20 | Remedy for osteoporosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH0352818A true JPH0352818A (en) | 1991-03-07 |
Family
ID=16216738
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP1188046A Pending JPH0352818A (en) | 1989-07-20 | 1989-07-20 | Remedy for osteoporosis |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0352818A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999026640A1 (en) * | 1997-11-20 | 1999-06-03 | Bukwang Pharm. Ind. Co., Ltd. | Pharmaceutical composition containing extracts of cervus nippon antlers having growth-stimulating activities of hematopoietic stem cells and megakaryocytes |
| CN104547750A (en) * | 2015-01-09 | 2015-04-29 | 周恩昌 | Traditional Chinese medicine composition for treating senile osteoporosis |
| CN105169085A (en) * | 2015-10-27 | 2015-12-23 | 孙启钊 | Traditional Chinese medicine composite for treating hyperthyroidism osteoporosis |
| CN105267654A (en) * | 2015-10-15 | 2016-01-27 | 李涛 | Preparation for treating osteoporosis and preparation method |
| US20170087176A1 (en) * | 2015-09-29 | 2017-03-30 | Johnson & Johnson Consumer Inc. | Composition for dust particle reduction |
-
1989
- 1989-07-20 JP JP1188046A patent/JPH0352818A/en active Pending
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999026640A1 (en) * | 1997-11-20 | 1999-06-03 | Bukwang Pharm. Ind. Co., Ltd. | Pharmaceutical composition containing extracts of cervus nippon antlers having growth-stimulating activities of hematopoietic stem cells and megakaryocytes |
| CN104547750A (en) * | 2015-01-09 | 2015-04-29 | 周恩昌 | Traditional Chinese medicine composition for treating senile osteoporosis |
| US20170087176A1 (en) * | 2015-09-29 | 2017-03-30 | Johnson & Johnson Consumer Inc. | Composition for dust particle reduction |
| US10980827B2 (en) * | 2015-09-29 | 2021-04-20 | Johnson & Johnson Consumer Inc. | Composition for dust particle reduction |
| CN105267654A (en) * | 2015-10-15 | 2016-01-27 | 李涛 | Preparation for treating osteoporosis and preparation method |
| CN105169085A (en) * | 2015-10-27 | 2015-12-23 | 孙启钊 | Traditional Chinese medicine composite for treating hyperthyroidism osteoporosis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004250445A (en) | Glycation inhibitor and its use | |
| JP2001506227A (en) | Medicinal chewing gum with favorable taste including inclusion complex | |
| RU2203079C2 (en) | Herbs composition and method of preparing said composition for treatment of gynecologic disorders | |
| KR950013752B1 (en) | Spray dried acetaminophen | |
| US6291462B1 (en) | Oral medicinal preparations with reproducible release of the active ingredient gatifloxacin or its pharmaceutically suitable salts or hydrates | |
| JPH0352818A (en) | Remedy for osteoporosis | |
| JP2525484B2 (en) | Osteoporosis treatment | |
| JP5523663B2 (en) | Pharmaceutical composition for promoting root-periodontal tissue formation | |
| KR101175120B1 (en) | Nateglinide-containing preparation | |
| RU2233666C1 (en) | Drone breed-base tablet "apilar" eliciting anabolic and actoprotective effect | |
| AU671536B2 (en) | A process for the preparation of substantially alcohol free pharmaceutical compositions | |
| JPH04169536A (en) | Therapeutic agent for osteoporosis | |
| CN101003829A (en) | Polypeptide of seed of spine date, preparation method, and application | |
| JPH07138175A (en) | Oxygen of ginseng saponin | |
| RU2017430C1 (en) | Composition for producing chewing gum | |
| JP3178763B2 (en) | Simanol sulfate manufacturing method | |
| KR100497945B1 (en) | Extract of herb for promoting release of growth hormone | |
| JP4594864B2 (en) | Follicle stimulating hormone reducing agent | |
| JP2002020299A (en) | Placenta-containing sublingual tablet | |
| JPH11103801A (en) | Composition containing quinua skin and food | |
| JP2004269395A (en) | Hypotensive action-having composition | |
| KR100518686B1 (en) | Extract of herb for promoting release of growth hormone | |
| JPH10236970A (en) | Antihistamic antagonist | |
| JP2001037443A (en) | New substance, its production and use thereof | |
| JPH04356414A (en) | Composition for removing or suppressing halitosis |